Rock Springs Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.36M Hold
257,460
0.14% 85
2025
Q4
$4.12M Buy
257,460
+21,233
+9% +$619K 0.21% 77
2025
Q3
$11M Buy
236,227
+152,245
+181% +$5.6M 0.64% 50
2025
Q2
$2.46M Buy
83,982
+900
+1% +$24.5K 0.15% 75
2025
Q1
$2.14M Buy
83,082
+53,777
+184% +$1.32M 0.12% 78
2024
Q4
$846K Buy
+29,305
New +$893K 0.03% 100
2022
Q2
Sell
-255,822
Closed -$9.13M 139
2022
Q1
$9.13M Sell
255,822
-41,165
-14% -$2.58M 0.23% 84
2021
Q4
$25.8M Buy
296,987
+314
+0.1% +$26K 0.6% 53
2021
Q3
$34M Sell
296,673
-10,718
-3% -$1.59M 0.72% 47
2021
Q2
$66.1M Buy
+307,391
New +$53.5M 1.31% 21

Other funds holding LENZ

Rock Springs Capital Management's LENZ Position: Q1 2026 in Review

Rock Springs Capital Management held its LENZ Therapeutics (LENZ) position steady in Q1 2026 at 257,460 shares worth $2.36M. The position accounts for 0.14% of the portfolio, ranked #85.

Rock Springs Capital Management first reported a position in LENZ in Q2 2021 and has held it in 10 quarters since. The position peaked at $66.1M in Q2 2021. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Rock Springs Capital Management held 257,460 shares of LENZ Therapeutics worth $2.36M as of Q1 2026.
  • Rock Springs Capital Management left its LENZ Therapeutics share count unchanged in Q1 2026.
  • LENZ Therapeutics made up 0.14% of Rock Springs Capital Management's portfolio in Q1 2026, its #85 holding.
  • Rock Springs Capital Management first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • Rock Springs Capital Management's LENZ Therapeutics position peaked at $66.1M in Q2 2021.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.